← Back to Search

Pharmacogenomic Testing for Cancer

N/A

Waitlist Available

Led By Jai Patel, PharmD

Research Sponsored by Wake Forest University Health Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥ 18 years at the time of consent

Be older than 18 years old

Must not have

History of prior allogeneic hematopoietic cell transplantation or liver transplantation

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, at 3 months and at 6 months after receiving the microarray profiling results

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to study how a genetic test called microarray PGx can affect the way doctors prescribe medications and cancer treatments to cancer patients who normally undergo single-gene DPYD testing.

Who is the study for?

This trial is for cancer patients eligible for DPYD gene testing, which helps tailor drug dosing. Specifics about who can join are not provided, but typically participants have a certain type of cancer and meet other health standards.

What is being tested?

The study tests the 'Global Diversity Array with Enhanced PGx' microarray to see if it affects how doctors prescribe and dose cancer treatments compared to current single-gene testing methods.

What are the potential side effects?

Since this trial involves genetic testing rather than drug treatment, there are no direct side effects from the intervention itself.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have had a bone marrow or liver transplant in the past.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, at 3 months and at 6 months after receiving the microarray profiling results

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, at 3 months and at 6 months after receiving the microarray profiling results

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, at 3 months and at 6 months after receiving the microarray profiling results for reporting.